Global inactivation of carboxylesterase 1 (Ces1/Ces1g) protects against atherosclerosis in Ldlr−/− mice

被引:0
|
作者
Jiesi Xu
Yang Xu
Yanyong Xu
Liya Yin
Yanqiao Zhang
机构
[1] Northeast Ohio Medical University,Department of Integrative Medical Sciences
[2] Institute of Genetics and Developmental Biology,State Key Laboratory of Molecular Developmental Biology
[3] Chinese Academy of Sciences,undefined
来源
Scientific Reports | / 7卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Atherosclerotic cardiovascular disease is a leading cause of death in the western world. Increased plasma triglyceride and cholesterol levels are major risk factors for this disease. Carboxylesterase 1 (Ces1/Ces1g) has been shown to play a role in metabolic control. So far, the role of mouse Ces1/Ces1g deficiency in atherosclerosis is not elucidated. We generated Ces1/Ces1g−/− mice. Compared to wild-type mice, Ces1/Ces1g−/− mice had reduced plasma cholesterol levels. We then generated Ces1g−/−Ldlr−/− double knockout (DKO) mice, which were fed a Western diet for 16 weeks. Compared to Ldlr−/− mice, DKO mice displayed decreased plasma cholesterol and TG levels and reduced atherosclerotic lesions. Interestingly, knockdown of hepatic Ces1/Ces1g in Apoe−/− mice resulted in hyperlipidemia and exacerbated Western diet-induced atherogenesis. Mechanistically, global inactivation of Ces1/Ces1g inhibited intestinal cholesterol and fat absorption and Niemann-Pick C1 like 1 expression, and increased macrophage cholesterol efflux by inducing ATP-binding cassette subfamily A member 1 (ABCA1) and ABCG1. Ces1/Ces1g ablation also promoted M2 macrophage polarization and induced hepatic cholesterol 7α-hydroxylase and sterol 12α-hydroxylase expression. In conclusion, global loss of Ces1/Ces1g protects against the development of atherosclerosis by inhibiting intestinal cholesterol and triglyceride absorption and promoting macrophage cholesterol efflux.
引用
收藏
相关论文
共 50 条
  • [21] Carboxylesterase 1 (CES1) regulates arachidonic acid-containing triacylglycerol levels in macrophages and shapes their immunophenotype
    Adekanye, Oluwabori
    Phillips, Maggie
    Borazjani, Abdolsamad
    Ross, Matthew
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2023, 299 (03) : S444 - S444
  • [22] Randomized evaluation of the loss-of-function carboxylesterase 1 (CES1) G143E variant on clopidogrel and ticagrelor pharmacodynamics
    Lewis, Joshua P.
    Ryan, Kathleen A.
    Streeten, Elizabeth A.
    Whitlatch, Hilary B.
    Daue, Melanie
    Tanner, Keith
    Perry, James A.
    O'Connell, Jeffrey R.
    Shuldiner, Alan R.
    Mitchell, Braxton D.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (11):
  • [23] Revealing human carboxylesterase 1 (CES1) sequence-dependent activity variations using fluorescent chemical tools
    Beck, Michael W.
    FASEB JOURNAL, 2022, 36
  • [24] Carbonate-Based Fluorescent Chemical Tool for Uncovering Carboxylesterase 1 (CES1) Activity Variations in Live Cells
    Singh, Anchal
    Gao, Mingze
    Karns, Carolyn J.
    Spidle, Taylor P.
    Beck, Michael W.
    CHEMBIOCHEM, 2022, 23 (12)
  • [25] Population Pharmacokinetics of Methylphenidate in Healthy Adults Emphasizing Novel and Known Effects of Several Carboxylesterase 1 (CES1) Variants
    Lyauk, Y. K.
    Stage, C.
    Bergmann, T. K.
    Ferrero-Milliani, L.
    Bjerre, D.
    Thomsen, R.
    Dalhoff, K. P.
    Rasmussen, H. B.
    Jurgens, G.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2016, 9 (06): : 337 - 345
  • [26] Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man:: Clinical significance and molecular basis
    Zhu, Hao-Jie
    Patrick, Kennerly S.
    Yuan, Hong-Jie
    Wang, Jun-Sheng
    Donovan, Jennifer L.
    DeVane, C. Lindsay
    Malcolm, Robert
    Johnson, Julie A.
    Youngblood, Geri L.
    Sweet, Douglas H.
    Langaee, Tairnour Y.
    Markowitz, John S.
    AMERICAN JOURNAL OF HUMAN GENETICS, 2008, 82 (06) : 1241 - 1248
  • [27] A Comprehensive Functional Assessment of CES1 Nonsynonymous Variants
    Wang, Xinwen
    Rida, Nada
    Shi, Jian
    Zhu, Hao-Jie
    FASEB JOURNAL, 2017, 31
  • [28] Reappraisal of the genetic diversity and pharmacogenetic assessment of CES1
    Ferrero-Miliani, Laura
    Bjerre, Ditte
    Stage, Claus
    Madsen, Majbritt Busk
    Jurgens, Gesche
    Dalhoff, Kim Peder
    Rasmussen, Henrik Berg
    PHARMACOGENOMICS, 2017, 18 (13) : 1241 - 1257
  • [29] Pharmacogenetic study of CES1 gene and enalapril efficacy
    Hussain, Misbah
    Basheer, Sehrish
    Khalil, Adila
    Haider, Qurat Ul Ain
    Saeed, Hafsa
    Faizan, Muhammad
    JOURNAL OF APPLIED GENETICS, 2024, 65 (03) : 463 - 471
  • [30] Structural organization and characterization of the regulatory element of the human carboxylesterase (CES1A1 and CES1A2) genes
    Hosokawa, Masakiyo
    Furihata, Tomomi
    Yaginuma, Yumiko
    Yamamoto, Naoko
    Watanabe, Natsuko
    Tsukada, Eiko
    Ohhata, Yoshiko
    Kobayashi, Kaoru
    Satoh, Testuo
    Chiba, Kan
    DRUG METABOLISM AND PHARMACOKINETICS, 2008, 23 (01) : 73 - 84